Coherus Neulasta Biosimilar Autoinjector Gets FDA Approval
The US Food and Drug Administration has approved the use of an autoinjector version ofUdenyca Coherus Biosciences biosimilar to Amgen’s Neulasta, a drug that reduces the chance of developing febrile neutropenia after chemotherapy. While this is the first approved autoinjector version of the drug, it’s far from the only biosimilar.
Polpharma Files for EU Approval of Tysabri Biosimilar
Polpharma Biologics has filed for approval in the EU for its biosimilar of Tysabri, Biogen’s multiple sclerosis (MS) therapy. The application is the first of its kind in the EU, and covers the intravenous version of the drug. Biogen originally had 5 more years of exclusivity, but a key patent for the drug was revoked in a European court last year.
Congressional Budget Office Releases Prescription Drugs Spending, Use, and Pricing Report
Results from a recently released Congressional Budget Office (CBO) prescription drugs report found drops in net prices for prescriptions in [...]
Lower-cost Biosimilars Blocked from Market by Patent Thickets
A new study finds that only 6% of patents for biologic medicines are for key ingredients. In contrast, 42% cover [...]
Abbvie Calls for U.S. International Trade Commission Investigation of Alvotech’s Humira Biosimilar
The manufacturer Abbvie has formally asked the U.S. International Trade Commission to investigate Alvotech’s lower-cost Humira biosimilar. Alvotech has faced [...]
Cigna’s New Shared Savings Program Offers $500 if Members Convert to Biosimilars as Billion Dollar Savings Loom
Cigna has launched a Shared Savings Program, aimed at reducing costs for its members by identifying alternative drugs offered at [...]
Biosimilars Key to Capitalizing on Trump’s Favored Nations Order
President Trump recently signed an executive order that lowers prescription drug costs by tying US drug prices to prices paid [...]
Gaps in Biosimilar Assessment Reports Pique Investigator Interest
According to a recent evaluation of health technology assessments (HTAs) for biosimilars, researchers found the majority of HTAs lack systematic [...]
